TY - JOUR
T1 - Differentiation of lethal and non lethal prostate cancer
T2 - PSA and PSA isoforms and kinetics
AU - Ballentine Carter, H.
PY - 2012/5
Y1 - 2012/5
N2 - Prostate-specific antigen (PSA) testing for the early diagnosis of prostate cancer has led to a decrease in cancer mortality. However, the high prevalence of low-grade prostate cancer and its long natural history, competing causes of death in older men and treatment patterns of prostate cancer, have led to dramatic overtreatment of the disease. Improved markers of prostate cancer lethality are needed to reduce the overtreatment of prostate cancer that leads to a reduced quality of life without extending life for a high proportion of men. The PSA level prior to treatment is routinely used in multivariable models to predict prostate cancer aggressiveness. PSA isoforms and PSA kinetics have been associated with more aggressive phenotypes, but are not routinely employed as part of prediction tools prior to treatment. PSA kinetics is a valuable marker of lethality post treatment and routinely used in determining the need for salvage therapy.
AB - Prostate-specific antigen (PSA) testing for the early diagnosis of prostate cancer has led to a decrease in cancer mortality. However, the high prevalence of low-grade prostate cancer and its long natural history, competing causes of death in older men and treatment patterns of prostate cancer, have led to dramatic overtreatment of the disease. Improved markers of prostate cancer lethality are needed to reduce the overtreatment of prostate cancer that leads to a reduced quality of life without extending life for a high proportion of men. The PSA level prior to treatment is routinely used in multivariable models to predict prostate cancer aggressiveness. PSA isoforms and PSA kinetics have been associated with more aggressive phenotypes, but are not routinely employed as part of prediction tools prior to treatment. PSA kinetics is a valuable marker of lethality post treatment and routinely used in determining the need for salvage therapy.
KW - PSA kinetics
KW - benign PSA
KW - human kallikrein 2
KW - precursor form of PSA
KW - prostate specific antigen
KW - unbound or free PSA
UR - http://www.scopus.com/inward/record.url?scp=84860856485&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84860856485&partnerID=8YFLogxK
U2 - 10.1038/aja.2011.141
DO - 10.1038/aja.2011.141
M3 - Review article
C2 - 22343493
AN - SCOPUS:84860856485
SN - 1008-682X
VL - 14
SP - 355
EP - 360
JO - Asian Journal of Andrology
JF - Asian Journal of Andrology
IS - 3
ER -